분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-03-31 12:41:38 , Hit : 974
 Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV


PBR Staff Writer
Published 27 March 2015
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Gilead Sciences' Sovaldi (sofosbuvir) for the suppression of viremia in patients with genotype 2 chronic hepatitis C virus (HCV) infection with or without compensated cirrhosis.


Sovaldi, a once-daily nucleotide analog polymerase inhibitor, is indicated for use in combination with ribavirin (RBV) for 12 weeks and the combination is the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection.

The approval is based on data from a Phase III trial conducted in Japan (Study GS-US-334-0118) among treatment-naïve and treatment-experienced genotype 2 patients.

In the trial, 96% of genotype 2 HCV-infected patients received 12 weeks of an all-oral regimen of Sovaldi plus RBV 600-1,000mg/day achieving a sustained virologic response 12 weeks after completing therapy (SVR12).

Gilead Research and Development executive vice-president and chief scientific officer Norbert Bischofberger said: "There is a need in Japan for new HCV treatment options that are more effective and better tolerated and we have been pleased to partner with the medical community here in Japan to demonstrate the efficacy and safety of Sovaldi.

"We look forward to making Sovaldi available in Japan as quickly as possible, while simultaneously continuing to work with the agency on its review of our second application for an all-oral sofosbuvir-based regimen for the treatment of genotype 1 HCV infection."

The Japanese approval is also supported by SVR12 results from four international Phase III trials FISSION, FUSION, POSITRON and VALENCE, which included genotype 2 HCV patients.

The company said that patients who achieve SVR12 are considered cured of HCV infection.

In September 2014, the company filed a new drug application (NDA) in Japan for a single-tablet regimen of sofosbuvir and the NS5A inhibitor ledipasvir to treat genotype 1 HCV infected patients.








1047   환기불량이 한국에서 MERS 슈퍼전파를 일으켰을까?  이성욱 2015/06/09 1264
1046   제브라 피쉬의 새로운 역할 : 대규모의 유전자 기능 연구  이성욱 2015/06/09 1204
1045   세균의 도구로 식물 DNA 편집  이성욱 2015/06/09 1039
1044   한국에서 MERS 폭발사태를 야기한 슈퍼전파 사건  이성욱 2015/06/04 930
1043   의문이 제기된 `젊은 피`의 항노화 효과  이성욱 2015/05/22 1125
1042   옥스포드 나노포어, 휴대용 시퀀서 미니온 출시 임박  이성욱 2015/05/08 1089
1041   맹인을 위한 유전자치료의 쇠퇴  이성욱 2015/05/08 1168
1040   인간 노화 조절 가능하다  이성욱 2015/05/04 1532
1039   세부모 배아의 대안적 방법  이성욱 2015/04/29 1030
1038   중국의 인간배아 유전자편집 연구를 바라보는 상반된 시각  이성욱 2015/04/28 1370
1037   유전자 조작인간배아를 만들어낸 중국과학자들  이성욱 2015/04/27 1038
1036   항체를 이용한 HIV치료법  이성욱 2015/04/15 981
1035   CRISPR의 능력을 배가(倍加)시키는 미니 유전자  이성욱 2015/04/02 1151
1034   여러 질환에 대한 치료제의 가능성을 보여준 신물질  이성욱 2015/03/31 997
1033   안젤리나 졸리 이번엔 난소 절제, `졸리 효과` 부활하나?  이성욱 2015/03/31 999
  Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV  이성욱 2015/03/31 974
1031   수지상 세포의 항암 작용을 향상시키는 갑상선 호르몬  이성욱 2015/03/30 1213
1030   화학적 태그로 미래의 마이크로 RNA 표시  이성욱 2015/03/30 1483
1029   생명탄생의 수수께끼를 해결한 화학자들  이성욱 2015/03/18 969
1028   흔한 헤르페스 약물, 헤르페스 감염과는 별도로 HIV-1 수준 낮춘다.  이성욱 2015/03/17 1582

[이전 10개] [1]..[11] 12 [13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN